Valsartan appears more effective than amlodipine in preventing HF, diabetes in patients with hypertension


An angiotensin receptor blocker (ARB) valsartan-based regimen offered advantages over a calcium channel blocker (CCB) amlodipine-based regimen in preventing heart failure (HF) and diabetes in patients with hypertension, according to results of an analysis published in Hypertension.

Related Content
© 2023 MJH Life Sciences

All rights reserved.